In the treatment of children with epilepsy, the role of topiramate has been expanding gradually. The main factor that has contributed to this trend is the relatively large body of information that has accumulated on the clinical pharmacology of topiramate in children, including its broad-spectrum efficacy, pediatric pharmacokinetics, side-effect profile, and safety. It has also become increasingly apparent with time that topiramate, in contrast to other broad-spectrum antiepileptic drugs used in children, does not seem to be associated with a significant risk of any serious or life-threatening adverse effects. The present review summarizes the available evidence related to the clinical pharmacology of topiramate in children and provides an update on its known mechanisms of action. Finally, available experimental data on the neuroprotective effect of topiramate are reviewed because of their considerable clinical potential in the treatment of children and newborns. (J Child Neurol 2000;15:S27-S30).
Get full access to this article
View all access options for this article.
References
1.
Elterman RD, Glauser TA, Wyllie et al: A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology1999;52:1338-1344.
2.
Biton V., Montouris GD, Ritter F., et al: A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology1999;52:1330-1337.
3.
Sachdeo RC, Glauser TA, Ritter F., et al: A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology1999;52:1882-1887.
4.
Glauser TA, Clark PO, Strawsburg R.: A pilot study of topiramate in the treatment of infantile spasms. Epilepsia1998;39:1324-1328.
5.
Shorvon S.: Safety of topiramate: Adverse events and relationships to dosing. Epilepsia1996;37(Suppl 2):S18-S22.
6.
Wasserstein A., Rak I., Reife R.: Nephrolithiasis during treatment with topiramate, abstract. Epilepsia1995;36(Suppl 3):S153.
7.
Wilner A., Raymond K., Pollard R.: Topiramate and metabolic acidosis. Epilepsia1999;40:792-795.
8.
Takeoka M., Holmes GH, Thiele E., et al: Topiramate and metabolic acidosis in pediatric epilepsy, abstract . Epilepsia1999;40(Suppl 7):127.
9.
Bourgeois BFD : Pharmacokinetics and metabolism of topiramate . Drugs of Today1999;35:43-48.
10.
Bourgeois BFD : Drug interaction profile of topiramate. Epilepsia1996;37(Suppl 2):S14-S17.
11.
Bourgeois BFD : Important pharmacokinetic properties of antiepileptic drugs. Epilepsia1995;36(Suppl 5):1-7.
12.
Bourgeois BFD : Pharmacokinetic properties of current antiepileptic drugs: What improvements are needed? Neurology2000; 55(Suppl 1):S12-S17.
13.
Rosenfeld WE , Doose DR, Walker SA, Nayak RK: Effects of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethynil estradiol in patients with epilepsy. Epilepsia1997;38:317-323.
14.
Liao S., Palmer M.: Digoxin and topiramate drug interaction study in male volunteers, abstract . Pharm Res1993; 10(Suppl): S444.
15.
Rosenfeld WE , Doose DR, Walker SA, et al: A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol1999;20:339-344.
16.
Glauser TA, Miles MV, Tang P., et al: Topiramate pharmacokinetics in infants. Epilepsia1999;40:788-791.
17.
Doose DR, Walker SA, Scott W., et al: The comparative bioavailability of topiramate from two investigational pediatric sprinkle formulations relative to a tablet formulation, abstract . Epilepsia1996;37 (Suppl 5):112.
18.
Doose DR, Walker SA, Baldassare J.: The effect of food on the oral bioavailability of topiramate from an investigational pediatric sprinkle formulation, abstract. Epilepsia1997;38(Suppl 3):147.
19.
Gibbs JW, Sombati S., DeLorenzo RJ, Coulter DA: Cellular actions of topiramate: Blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia2000;41(Suppll):S10-S16.
20.
Skradski S. , White HS: Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia2000;41(Suppl 1):S45-S47.
21.
White HS, Brown SD, Woodhead JH, et al: Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia2000;41(Suppl 1):S17-S20.
22.
Coulter DA, Sombati S., DeLorenzo RJ: Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons, abstract. Epilepsia1993;34(Suppl 2):123.
23.
DeLorenzo RJ , Sombati S., Coulter DA: Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia2000;41(Suppl 1):S40-S44.
24.
McLean MJ, Bukhari AA, Wamil AW: Effects of topiramate on sodium-dependent action potential firing by mouse spinal cord neurons in cell culture. Epilepsia2000;41(Suppl 1):S21-S24.
25.
Zhang X., Velumian AA, Jones OT, Carlen PL: Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia2000;41(Suppl 1):S52-S60.
26.
Dodgson SJ, Shank RP, Maryanoff BE: Topiramate as an inhibitor of carbonic anhydrase isozymes. Epilepsia2000;41(Suppl 1): S35-S39.
27.
Edmonds HL, Jiang D., Zhang YP, et al: Topiramate as a neuroprotectant and anticonvulsant in postischemic injury, abstract. Epilepsia1992;33(Suppl 3):118.
28.
Angehagen M. , Hansson E., Ronnback L., Ben-Menachem E.: Does topiramate (TPM) have protective effects on astroglia cells and neurons in primary cortical cultures?, abstract. Epilepsia1998;39(Suppl 6):44.
29.
Angehagen M. , Hansson E., Ronnback L., Ben-Menachem E.: Topiramate alters glutamate induced [CA2+]i changes in neurons and astroglial cells in primary culture, abstract. Epilepsia1999 ;40(Suppl 7):16.
30.
Yang Y., Shuaib A., Li Q., Siddiqui MM: Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res1998;804:169-176.
31.
Yang Y., Li Q., Shuaib A.: Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate . Neuro-pharmacology2000;39:881-888.
32.
Koh S., Jensen FE: Topiramate blocks acute and chronic epileptogenesis in a rat model of perinatal hypoxic encephalopathy, abstract. Epilepsia1999;40(Suppl 7):5.
33.
Niebauer M. , Gruenthal M.: Topiramate reduces neuronal injury after experimental status epilepticus. Brain Res1999;837:263-269.
34.
Lee SR, Kim SP, Kim JE: Protective effect of topiramate against hippocampal neuronal damage after global ischemia in the gerbils. Neurosci Lett2000;281:183-186.
